These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Diffuse chorioretinal atrophy after a single standard low- dose intravitreal melphalan injection in a child with retinoblastoma: a case report. Chao A, Kao LY, Liu L, Wang NK. BMC Ophthalmol; 2016 Mar 15; 16():27. PubMed ID: 26975871 [Abstract] [Full Text] [Related]
3. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study. Francis JH, Schaiquevich P, Buitrago E, Del Sole MJ, Zapata G, Croxatto JO, Marr BP, Brodie SE, Berra A, Chantada GL, Abramson DH. Ophthalmology; 2014 Sep 15; 121(9):1810-7. PubMed ID: 24819859 [Abstract] [Full Text] [Related]
4. Intravitreal melphalan hydrochloride vs propylene glycol-free melphalan for retinoblastoma vitreous seeds: Efficacy, toxicity and stability in rabbits models and patients. Bogan CM, Pierce JM, Doss SD, Tao YK, Chen SC, Boyd KL, Liao A, Hsieh T, Abramson DH, Francis JH, Friedman DL, Richmond A, Daniels AB. Exp Eye Res; 2021 Mar 15; 204():108439. PubMed ID: 33444583 [Abstract] [Full Text] [Related]
5. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results. Shields CL, Manjandavida FP, Arepalli S, Kaliki S, Lally SE, Shields JA. JAMA Ophthalmol; 2014 Mar 15; 132(3):319-25. PubMed ID: 24407202 [Abstract] [Full Text] [Related]
6. Is intravitreal topotecan toxic to retinal function? Nadelmann J, Francis JH, Brodie SE, Muca E, Abramson DH. Br J Ophthalmol; 2021 Jul 15; 105(7):1016-1018. PubMed ID: 32665221 [Abstract] [Full Text] [Related]
7. Efficacy and Toxicity of Intravitreous Chemotherapy for Retinoblastoma: Four-Year Experience. Francis JH, Brodie SE, Marr B, Zabor EC, Mondesire-Crump I, Abramson DH. Ophthalmology; 2017 Apr 15; 124(4):488-495. PubMed ID: 28089679 [Abstract] [Full Text] [Related]
8. Alternated intra-arterial and intravitreal chemotherapy for advanced intraocular retinoblastoma: preliminary successful results without systemic chemotherapy. De Francesco S, Galluzzi P, Bracco S, Menicacci F, Motolese E, Hadjistilianou T. Int Ophthalmol; 2015 Dec 15; 35(6):887-95. PubMed ID: 26416040 [Abstract] [Full Text] [Related]
9. Not All Seeds Are Created Equal: Seed Classification Is Predictive of Outcomes in Retinoblastoma. Berry JL, Bechtold M, Shah S, Zolfaghari E, Reid M, Jubran R, Kim JW. Ophthalmology; 2017 Dec 15; 124(12):1817-1825. PubMed ID: 28655537 [Abstract] [Full Text] [Related]
10. Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma. Ghassemi F, Shields CL, Ghadimi H, Khodabandeh A, Roohipoor R. JAMA Ophthalmol; 2014 Aug 15; 132(8):936-41. PubMed ID: 24789622 [Abstract] [Full Text] [Related]
11. Pathological findings in enucleated eyes after intravitreal melphalan injection. Ghassemi F, Amoli FA. Int Ophthalmol; 2014 Jun 15; 34(3):533-40. PubMed ID: 24043335 [Abstract] [Full Text] [Related]
12. Intravitreal chemotherapy in the management of vitreous disease in retinoblastoma. Kiratli H, Koç İ, Varan A, Akyüz C. Eur J Ophthalmol; 2017 Jun 26; 27(4):423-427. PubMed ID: 28106239 [Abstract] [Full Text] [Related]
13. Combined intravitreal melphalan and intravenous/intra-arterial chemotherapy for retinoblastoma with vitreous seeds. Lee JH, Han JW, Hahn SM, Lyu CJ, Kim DJ, Lee SC. Graefes Arch Clin Exp Ophthalmol; 2016 Feb 26; 254(2):391-4. PubMed ID: 26511530 [Abstract] [Full Text] [Related]
14. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Ghassemi F, Shields CL. Arch Ophthalmol; 2012 Oct 26; 130(10):1268-71. PubMed ID: 23044940 [Abstract] [Full Text] [Related]